IRON

News Disc Medicine (IRON) Q2 Loss Widens 109%

14d ago

SEC filing IRON Reports $730M Cash, $63.5M Net Loss, Advances Phase 3 Bitopertin Enrollment, DISC-0974 ASCO Data, DISC-3405 PV/SCD Studies, $45.9M R&D Spend

28d ago

Insider trade Sale by William Jacob Savage (Chief Medical Officer)

47d ago

Insider trade Sale by Jean M. Franchi (Chief Financial Officer)

47d ago

Insider trade Sale by William Jacob Savage (Chief Medical Officer)

89d ago

Insider trade Sale by Jean M. Franchi (Chief Financial Officer)

94d ago

Insider trade Sale by John D Quisel (Chief Executive Officer)

104d ago

Insider trade Sale by Jonathan Yen-Wen Yu (Chief Operating Officer)

104d ago

Insider trade Sale by William Jacob Savage (Chief Medical Officer)

104d ago

Insider trade Sale by Pamela Stephenson (Chief Commercial Officer)

104d ago

Insider trade Sale by Rahul Khara (Chief Legal Officer)

104d ago

Insider trade Sale by Rahul Khara

104d ago

SEC filing IRON Receives FDA Complete Response Letter for Bitopertin, Requests APOLLO Study Results Before Approval

105d ago

News Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months

108d ago

News Disc Medicine plunges on FDA Complete Response Letter for bitopertin

108d ago

News FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks

138d ago

News Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers

138d ago

News Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

153d ago

News Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

153d ago

Scanner Unusual volume (z=13.7)

160d ago

Scanner Unusual volume (z=13.4)

162d ago

Scanner Unusual volume (z=13.4)

163d ago

Scanner Unusual volume (z=13.4)

164d ago

Insider trade Sale by Quisel John D (Chief Executive Officer)

168d ago